tradmap

SPRY Earnings Ars Pharmaceuticals, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$2 -$1 $0 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $45M $89M 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$171M -$82M $8M $0 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 -$1 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $43M $87M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$62M -$6M $50M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–20 of 20
Q2 20262026-06-30-1.242026-08-1310-Q
Q1 20262026-03-31-0.612026-05-1510-Q
FY 20252025-12-31-1.742026-03-0910-K
Q3 20252025-09-30-1.322025-11-1010-Q
Q2 20262025-06-30-0.802026-08-1310-Q
Q1 20262025-03-31-0.352026-05-1510-Q
FY 20252024-12-310.082026-03-0910-K
Q3 20252024-09-30-0.432025-11-1010-Q
Q2 20252024-06-30-0.242025-08-1310-Q
Q1 20252024-03-31-0.112025-05-1410-Q
FY 20242023-12-31-0.572025-03-2010-K
Q3 20242023-09-30-0.502024-11-1310-Q
Q2 20242023-06-30-0.342024-08-0610-Q
Q1 20242023-03-31-0.162024-05-0910-Q
FY 20232022-12-31-0.872024-03-2110-K
Q3 20232022-09-30-0.662023-11-0910-Q
Q2 20232022-06-30-0.452023-08-1010-Q
Q1 20232022-03-31-0.242023-05-1510-Q
FY 20222021-12-31-0.702023-03-2310-K
Q3 20222021-09-30-1.892022-11-0210-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.